Randomized, Phase II,Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine.

Trial Profile

Randomized, Phase II,Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Matuzumab; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors EMD Pharmaceuticals; EMD Serono
  • Most Recent Events

    • 01 Nov 2010 Primary endpoint 'Objective-clinical-response-rate' has not been met, according to Journal of Thoracic Oncology publication.
    • 01 Nov 2010 Results were published in the Journal of Thoracic Oncology.
    • 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top